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Abstract Insulin and leptin have overlapping effects in the
control of energy homeostasis, but the molecular basis of this
synergism is unknown. Insulin signals through a receptor tyrosine
kinase that phosphorylates and activates the docking proteins
IRSs (insulin receptor substrates), whereas the leptin receptor
and its associated protein tyrosine kinase JAK2 (Janus kinase 2)
mediate phosphorylation and activation of the transcription
factor STAT3 (signal transducer and activator of transcription).
Here, we present evidence for the integration of leptin and insulin
signals in the hypothalamus. Insulin induced JAK2 tyrosine
phosphorylation, leptin receptor phosphorylation which, in the
presence of leptin, augmented the interaction between STAT3
and this receptor. Insulin also increased the leptin-induced
phosphorylation of STAT3 and its activation. These results
indicate that insulin modulates the leptin signal transduction
pathway, and may provide a molecular basis for the coordinated
effects of insulin and leptin in feeding behavior and weight
control. ß 2001 Published by Elsevier Science B.V. on behalf
of the Federation of European Biochemical Societies.
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1. Introduction
The circulating peptide leptin, which is the product of the
ob gene [1], is secreted predominantly by white adipose tissue
and provides feedback information on the extent of the body’s
fat stores to central OB receptors (long form of the leptin
receptor (OBR)) [2] that control food intake and body weight
homeostasis [3,4]. The hypothalamus is thought to be the
major target for leptin, which acts through receptors that
bear strong sequence homology to the class I cytokine recep-
tor family [2]. The leptin receptor exists as multiple splice
variants. OBR is expressed most abundantly in paraventricu-
lar, arcuate and ventromedial nuclei of the hypothalamus,
where it mediates most of the neural signaling of leptin [5^
7]. Ligand binding to the OBR results in the activation of
Janus kinase 2 (JAK2) by transphosphorylation and the sub-
sequent phosphorylation of tyrosine residues on the intracel-
lular portion of OBR [8^11]. In general, tyrosine phosphory-
lation of cytokine and growth factor receptors activates
intracellular signals by recruiting speci¢c signaling proteins
with specialized phosphotyrosine-binding domains called src
homology 2 (SH2) domains [12,13]. Tyrosine phosphorylation
of OBR recruits the tyrosine phosphatase, phosphotyrosine
phosphatase 2 (SHP-2) [14,15] and the signal transducer and
activator of transcription (STAT3) transcription factor [14^
16]. The use of these SH2 domain-containing proteins by
OBR in the hypothalamus implies that they may mediate
physiologically important signals [17,18]. In addition to the
direct binding of SHP-2 and STAT3, OBR also mediates a
number of downstream actions in a variety of cells and tissues
[8].
Insulin acts in the same hypothalamic areas as leptin to
suppress feeding [19]. In the past decade, many of the proteins
involved in insulin action have been de¢ned at a molecular
level. The insulin receptor (IR) is a protein tyrosine kinase
which, when activated by insulin binding, undergoes rapid
autophosphorylation and phosphorylates intracellular protein
substrates, including insulin receptor substrates (IRSs) [20^
22], Shc [23] and Tub [24]. Following tyrosine phosphoryla-
tion, the IRSs act as docking proteins for several SH2 do-
main-containing proteins, including phosphatidylinositol 3-ki-
nase (PI 3-kinase), Grb2, SHP2, Nck and Fyn [25^29]. A
potential mitogen-activated protein kinase-independent mech-
anism for the regulation of gene expression is the JAK^STAT
pathway. The role of insulin in the activation of the JAK/
STAT pathway is controversial [30,31]. While this activation
was originally thought to occur through cytokine receptors,
recent work has shown that the key activating event, STAT
tyrosine phosphorylation, is regulated by receptor protein ty-
rosine kinases [32]. Furthermore, STAT5b activation by insu-
lin has also been reported [31]. However, there is no tyrosine
phosphorylation of STAT3 after stimulation by insulin [33].
Obesity in humans and rodents is usually associated with
high circulating levels of insulin and leptin as well as insulin
and leptin resistance [34^38]. The interaction between insulin
and leptin signaling pathways is therefore fundamental for an
integrated response of the signal inputs to the hypothalamus.
In this study, we examined the cross-talk between the signal-
ing pathways of insulin and leptin leading to STAT3 activa-
tion.
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2. Materials and methods
2.1. Animals and surgical procedures
Adult male Wistar rats (250^300 g) were used in all the experiments
in accordance with the guidelines of the Brazilian College for Animal
Experimentation (COBEA). After an overnight fast, the rats were
anesthetized with ketamine hydrochloride (100 mg/kg, i.p.) and posi-
tioned on a Stoelting stereotaxic apparatus using head and chin hold-
ers. An appropriate side arm holding the guide cannula was attached.
The vertical coordinate of the side arm was set at 0‡ in the lateral
plane and at 90‡ in the horizontal plane. The scalp was removed in the
midline to expose the saggital suture and the periosteum was then
opened and re£ected away from the surgical ¢eld. The lateral, ante-
roposterior and dorsoventral coordinates of the third ventricle were
obtained from a standard atlas [39]. The bregma was used as the
reference point and a hole was drilled in the parietal bone at the
junction of the lateral and anteroposterior coordinates. Two smaller
holes were drilled around this central hole, and stainless-steel screws
were inserted half-way through the holes. The cannula was positioned
over the central hole and lowered carefully until the necessary dorso-
ventral coordinate was reached. The cannula was ¢xed to the skull
using cranioplastic cement after ensuring hemostasis. After the cement
had set, the cannula was freed from the side arm and a dummy
cannula was inserted to close the outer cannula. The rats were then
allowed to recover from anesthesia and the surgical procedure for
7 days.
2.2. Intracerebroventricular infusions
After a 6-h fast, the rats were anesthetized with sodium amobarbital
(15 mg/kg body weight, i.p.), and used as soon as anesthesia was
assured by the loss of pedal and corneal re£exes. Insulin (1.9 Wg/Wl
^ human insulin from E. Lilly), leptin (5 Wg/Wl ^ rat leptin from NIH),
saline (2 Wl in the control animals) or an equimolar mixture of insulin
and leptin (1.9 Wg/Wl insulin, 5 Wg/Wl leptin) were taken up into an
internal fusion cannula connected to a polyethylene supply tube. This
tubing was then connected to a 2-Wl syringe primed with the infusate.
The dummy cannula was removed and the infusion cannula was in-
troduced into the outer guide cannula after which the solution was
injected into the third ventricle. The cranium was opened and the
hypothalamus excised. In preliminary experiments we determined
blood glucose and serum insulin levels in animals that received i.c.v.
insulin infusion. Insulinemia and glycemia were not altered by third
ventricle insulin or saline microinjection. Under the experimental con-
ditions, no retrograde insulin tra⁄cking through the blood^brain bar-
rier was observed.
2.3. Western blot analysis
The hypothalami were removed minced coarsely and homogenized
immediately in the solubilization bu¡er containing 100 mM Tris (pH
7.6), 1% Triton X-100, 150 mM NaCl, 0.1 mg aprotinin, 35 mg
PMSF/ml, 10 mM Na3VO4, 100 mM NaF, 10 mM Na4P207, and
4 mM EDTA, using a politron PTA 20S generator operated at max-
imum speed for 30 s and clari¢ed by centrifugation. Equal amounts of
protein were used for immunoprecipitation followed by Western blot
analysis with the indicated antibodies and 125I-Protein A. Quantitative
analysis of the blots was done using Scion Image software. The anti-
bodies to: OBR (SC-1835 and SC-8325), phosphotyrosine (SC-508),
STAT3 (SC-483), JAK2 (SC-294-G) were obtained from Santa Cruz
Biotechnology, and the STAT3 phosphotyrosine 705-speci¢c antibody
(9131) was from New England Biolabs.
2.4. IR kinase assay
IR tyrosine kinase activity was measured by autophosphorylation.
Insulin was infused into the third ventricle to stimulate limited recep-
tor activation and partial IR autophosphorylation. IR was then im-
munoprecipitated and allowed to autophosphorylate in vitro in the
presence of exogenous ATP. Tyrosine autophosphorylation was mea-
sured by immunoblotting with anti-phosphotyrosine antibody.
2.5. Nuclear extracts
Tissues were dissected and dounce-homogenized 10 times in 100:
1 (v:v) of bu¡er A (10 mM KCI, 1.5 mM MgCl2, 10 mM HEPES pH
7.9, 1 mM DTT, 1 mM NaVO4, lUcomplete TM protease inhibitor
(Boehringer Mannheim). After centrifugation at 2000Ug for 10 min
at 4‡C, the pellet was carefully resuspended in two volumes of bu¡er
B (420 mM NaCl, 10 mM KCI, 20 mM HEPES pH 7.9, 20% glycerol,
1 mM DTT, 1 mM Na VO4, 1Ucomplete TM protease inhibitor) and
extracted for 30 min at 4‡C on a shaking rotor. After centrifugation at
16 000Ug, the supernatant was diluted 10-fold in bu¡er C (10 mM
KCl, 20 mM HEPES pH 7.9, 20% glycerol, 1 mM DTT, 1 mM
NaVO4, 1U complete TM protease inhibitor) and centrifuged for
10 min at 16 000Ug. The supernatant was loaded onto a Microcon
50 ultra¢ltration column (Amicon) and centrifuged for 15 min at
4000Ug The protein concentration was determined by the Bradford
assay (Bio-Rad). Samples were snap-frozen and kept at 380‡C. The
procedure was carried out at 4‡C. DTT, NaVO4 and protease inhib-
itors were added at the time of the experiment.
2.6. Electrophoretic mobility shift assay (EMSA)
EMSA was done as described [40]. Double-stranded oligonucleotide
probes were synthesized with 5P-GATC protruding ends for ¢ll-in
labeling. The M67-SIE probe sequence was 5P-CATTTCCCG-
TAAATCAT-3P. 2 Wg of hypothalamic nuclear extract were incubated
at room temperature for 15 min in the presence of 100 pg of labeled
probe (2U104^105 dpm), 2 Wg de poly dI-dC (Pharmacia), 40 mM
KCI, 1 mM MgCl2, 20 mM HEPES pH 7,9, 100 WM EGTA, 0.5 mM
DTT and 4% Ficoll in a total volume of 12Wl. Samples were run on
4% native polyacrylamide gels in 0.25UTBE at 4‡C.
2.7. Statistical analysis
Where appropriate, the results were expressed as the mean þ S.E.M.
accompanied by the indicated number of experiments. ANOVA fac-
torial test was used in all statistical comparisons with P6 0.05 indi-
cating signi¢cance.
3. Results and discussion
The aim of this study was to examine the cross-talk between
the insulin and leptin signal transduction pathways in the
hypothalamus of normal rats. The rats were studied 7 days
after the implantation of a cannula in the third ventricle.
Leptin, insulin or both hormones were administered i.c.v.,
after which the ability of leptin to activate STAT3 in the
hypothalamus was assessed.
OBR has been detected in various hypothalamic regions,
including the arcuate nucleus [2,41], where it completes a feed-
back loop that delivers information on peripheral energy
stocks to the hypothalamus, thereby altering both food intake
Fig. 1. Di¡erent isoforms of OBR are present in the hypothalamus.
Hypothalamic lysates were run on 8% polyacrylamide gels and blot-
ted with antibody raised against amino acids 32^51 of the extracel-
lular domain of the OBR. Several bands representing the long and
short isoforms were detected. OBR migrated as a major band just
below the 208-kDa marker, whereas a band close to 116 kDa repre-
sented the short form. The bands migrating in the 60^85-kDa range
may represent degradation products of the leptin receptor.
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and metabolic rate. The presence of various isoforms of OBR
in hypothalamic extracts was analyzed by Western blotting
using a polyclonal antibody generated against amino acids
32^51 of the extracellular domain of the mouse OBR. The
hypothalamus expressed the long and short isoforms of the
OBR (Fig. 1). In agreement with data obtained using cells
transfected with OBR-S or OBR-L [8,9], OBR migrated as a
weak doublet band above the 208-kDa marker and as a major
band just below this marker; the short form migrated as a
minor band close to the 116-kDa marker. The bands at 60
kDa and 85 kDa were not characterized further and may
represent the non-glycosylated short form of the OBR or deg-
radation fragments as previously described in Fao cells [42].
The OBR is a member of the class I cytokine receptor
family that causes a ligand-dependent increase in intracellular
protein tyrosine phosphorylation which is essential for recep-
tor function [43]. Receptors of this class lack intrinsic tyrosine
kinase activity and act through receptor-associated kinases of
the Janus family (JAKs). Activated JAKs can phosphorylate
each other, the receptor and the recruited cellular substrates
[44]. To examine leptin-induced tyrosine phosphorylation of
JAK2, immunoprecipitation and Western blotting of hypo-
thalamic extracts were done using anti-JAK2 and anti-phos-
photyrosine antibodies, respectively. As shown in Fig. 2, there
was an increase in the phosphorylation of JAK2 1 min after
exposure to leptin. Maximal tyrosine phosphorylation of
JAK2 occurred 15^30 min after leptin infusion (Fig. 2A)
and then decreased dramatically (data not shown). This is
the ¢rst demonstration that such signaling, previously de-
scribed in cultured cells, occurs in the rat hypothalamus after
the i.c.v. infusion of leptin. These results di¡er from those of
McCowen et al. [45], who reported that leptin signaling was
distinguishable from that of GH and other ligands in this class
of receptors by its inability to stimulate JAK family proteins
in the rat hypothalamus. This discrepancy may re£ect the
Fig. 2. E¡ect of leptin on JAK2 phosphorylation. Hypothalamic ex-
tracts of from rats treated with 10 Wg of leptin for the indicated
times, were prepared as described in Section 2. A: Tissue extracts
were immunoprecipitated with anti-JAK2 (IP) and immunoblotted
with anti-phosphotyrosine antibody (pY) (IB, immunoblotting).
Quantitation of the phosphorylation of JAK2 protein is shown in
the bar graph, and represents the mean þ S.E.M. of four independ-
ent experiments. B: The equal loading of proteins was veri¢ed by
reblotting with anti-JAK2 antibodies. **P6 0.01, compared to rats
treated with saline (control) (factorial ANOVA).
Fig. 3. Insulin induces IR tyrosine kinase activity and JAK2 phosphorylation in rat hypothalamus. A: IR tyrosine kinase activity measured by
autophosphorylation. Insulin (10 ng) was injected into the third ventricle to partially stimulate IR autophosphorylation. The IR was then im-
munoprecipitated and allowed to autophosphorylate in vitro in the presence of exogenous ATP (lane 4). Tyrosine phosphorylation was mea-
sured by immunoblotting with an anti-phosphotyrosine antibody. Control conditions are shown in lanes 1^3. Lane 1: The hypothalamic extract
was not exposed to insulin nor was exogenous ATP added to the in vitro autophosphorylation reaction. Lane 2: A low dose of insulin (10 ng)
was infused into the third ventricle and the hypothalamus was then extracted, but no exogenous ATP was added during the autophosphoryla-
tion reaction in vitro. The faint signal seen in this lane probably represents IR autophosphorylation using endogenous ATP. Lane 3: The hypo-
thalamus was not exposed to insulin, but ATP was added to the autophosphorylation reaction in vitro. B: The equal loading of proteins was
veri¢ed by reblotting with anti-IR antibodies. Bar graphs are representative of ¢ve independent experiments (mean þ S.E.M.). **P6 0.01 com-
pared to rats treated with saline (control) (factorial ANOVA). In (C) and (D) extracts of bar graphs are representative of ¢ve independent ex-
periments (mean þ S.E.M.). Hypothalami from rats treated with 10 Wg leptin for the indicated times, were prepared as described in Section 2.
C: Tissue extracts were immunoprecipitated with anti-JAK2 (IP) and immunoblotted with anti-phosphotyrosine antibody (pY) (IB, immuno-
blotting). Quantitation of the phosphorylation of JAK2 protein is shown in the bar graph, and represents the mean þ S.E.M. of four independ-
ent experiments. D: The equal loading of proteins was veri¢ed by reblotting with anti-JAK2 antibodies. **P6 0.01 compared to rats treated
with saline (control) (factorial ANOVA).
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dephosphorylation of JAK2 by one of several phosphatases
during the storage and manipulation of hypothalamic tissue.
As demonstrated in other tissues, insulin stimulated IR au-
tophosphorylation and kinase activity in the rat hypothala-
mus (Fig. 3A,B). To investigate whether insulin could induce
JAK2 tyrosine phosphorylation in the rat hypothalamus, as
described in other tissues and cultured cells [30,46], we infused
insulin i.c.v. followed by immunoprecipitation and Western
blotting of hypothalamic extracts using anti-JAK2 and anti-
phosphotyrosine antibodies, respectively. As shown in Fig. 3,
maximal tyrosine phosphorylation of JAK2 occurred 1 min
after insulin infusion and disappeared by 15 min (Fig. 3C,D).
Insulin acts in the same hypothalamic areas as leptin to
suppress feeding [19]. We have performed immunohistochem-
ical analysis of rat hypothalami using IR- and OBR-speci¢c
antibodies and the results showed high concentrations of both
receptors in the arcuate nucleus and, to a lesser extent, in
some periventricular neuronal bodies (data not shown). The
presence of both receptors in the same hypothalamic areas
may allow a cross-talk between these two hormones. To de-
termine whether there was a direct interaction between the
insulin and leptin signaling systems, insulin, leptin or insulin
plus leptin were infused i.c.v. and OBR tyrosine phosphory-
lation was assessed. Immunoprecipitation and Western blot-
ting of hypothalamic extracts were done using the anti-leptin
receptor (SC 8325) and anti-phosphotyrosine antibodies, re-
spectively. As shown in Fig. 4A (right side), the leptin recep-
tor (the band just below 208 kDa) was strongly phosphory-
lated 15 and 30 min after an i.c.v. infusion of leptin. There
was also an increase in OBR tyrosine phosphorylation as
early as 5 min after exposure to insulin; maximal phosphor-
ylation occurred at 15 min and then decreased by 30 min after
insulin infusion (Fig. 4A, left side). Based on these results, we
hypothesized that insulin could interfere with the leptin signal-
ing system. When insulin was infused simultaneously with
leptin, the levels of OBR phosphorylation increased by
1.7 þ 0.2-fold (P6 0.01) compared with leptin treatment
alone. The mechanism by which insulin can induce leptin
receptor phosphorylation is unknown, but may involve
JAK2. In agreement with this hypothesis, the time-course of
Fig. 4. E¡ect of insulin and leptin on OBR phosphorylation and
STAT3 association in extracts of hypothalami from rats treated
with leptin, insulin or a combination of the two for the indicated
times. A: Western blots of anti-OBR immunoprecipitates (IP) with
anti-phosphotyrosine antibody (pY) (IB, immunoblotting). The bar
graph shows the quantitative phosphorylation of OBR proteins. B:
The same membranes were reblotted with anti-STAT3 antibodies.
The bar graph represents the quantitative association of STAT3
with OBR. The data in (A) and (B) are the means þ S.E.M. of four
to six independent experiments. C: The equal loading of proteins
was veri¢ed by reblotting with OBR antibodies. *P6 0.05 and
**P6 0.01 vs. control; VVP6 0.01 vs. leptin-treated rats (factorial
ANOVA).
Fig. 5. Insulin (Ins) does not induce STAT3 activation but positively modulates leptin-induced activation of this protein. A: Hypothalami were
stimulated with insulin, leptin (Lep), or a combination of the two for the indicated times. Hypothalami were lysed and the proteins were sepa-
rated by SDS^PAGE on 8% gels and blotted with phosphotyrosine-speci¢c STAT.3 antibodies. Leptin, but not insulin increased the phosphory-
lation of STAT3; combining the two hormones increased the phosphorylation compared to leptin alone. A representative Western blotting of
each is shown. The bar graphs represent the means þ S.E.M. of three to four independent experiments. B: Insulin- and leptin-induced STAT3
DNA-binding activity in rat hypothalami. Rats were starved for 6 h and then received leptin, insulin or insulin plus leptin. The animals were
sacri¢ced at the indicated times, and nuclear extractions were used for EMSA (see Section 2). Each lane represents four hypothalami. All ex-
periments were done twice with similar results. A representative gel shift is shown for each treatment. *P6 0.05 and **P6 0.01 vs. control;
VVP6 0.01 vs. leptin-treated rats (factorial ANOVA).
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insulin-induced JAK2 tyrosine phosphorylation preceded that
of OBR phosphorylation.
Tyrosine phosphorylation of the OBR leads to the binding
of STAT3 [47]. To detect the OBR/STAT3 association, nitro-
cellulose membranes containing samples previously immuno-
precipitated with anti-OBR antibody were blotted with anti-
STAT3 antibodies. There was an increase in OBR/STAT3
association after leptin stimulation, and this was concomitant
with the increase in OBR tyrosine phosphorylation (Fig. 4B,
right side). The same membrane was reprobed with anti-IR
antibody, and no band was detected, demonstrating that there
was not non-speci¢c antibody interaction. Insulin was also
able to recruit STAT3 to OBR (Fig. 4B, left side). This in-
sulin-induced increase in the OBR recruitment of STAT3 in-
dicated that insulin can modulate the OBR. The simultaneous
stimulation with leptin and insulin dramatically increased this
association compared to leptin treatment alone (Fig. 4B).
To determine the additive e¡ect of insulin on the leptin
signal transduction pathway, we evaluated the activity of
STAT3 after the infusion of these hormones (Fig. 5A,B). Ini-
tially, we measured insulin-induced tyrosine phosphorylation
of STAT3 by immunoblotting with speci¢c phospho-STAT3
antibodies. As shown in Fig. 5A, insulin did not induce tyro-
sine phosphorylation of STAT3. Western blotting was also
used to examine the tyrosyl phosphorylated STAT3 proteins
before and after stimulation with leptin. Fig. 5A shows that
there was a marked increase in leptin-stimulated STAT3 phos-
phorylation in rat hypothalami which was maximal at 15 min.
Comparison of the bands from simultaneous stimulation re-
vealed that the extent of STAT3 phosphorylation increased
2.1 þ 0.4-fold (P6 0.05) in rats receiving leptin plus insulin
compared to the leptin-treated group. The results were con-
¢rmed by EMSA experiments. A time-course curve for
STAT3 activation after i.c.v. leptin administration in normal
rats showed an increase in STAT3 nuclear binding after stim-
ulation with this hormone. The maximal response was ob-
tained immediately after tyrosine phosphorylation, i.e. 15^30
min after 10 Wg of leptin i.c.v. and was similar to the maximal
response time observed after the iv injection of leptin [17]. In
agreement with the results for STAT3 phosphorylation, there
was no STAT3 activation after stimulation with insulin. How-
ever, the simultaneous administration of insulin and leptin
increased the activation of STAT3 by 1.9 þ 0.5-fold compared
to treatment with leptin alone. These ¢ndings indicate that
insulin modulates leptin signal transduction by increasing
the association of the leptin receptor with STAT3, leading
to activation of the latter.
Based on these results we propose a model for the cross-
talk between the insulin and leptin pathways in rat hypothal-
amus (Fig. 6). According to this model insulin alone induces
IR tyrosine phosphorylation which is rapidly followed by
JAK2 tyrosine phosphorylation. Activated JAK2 then induces
the phosphorylation of OBR. This pathway leads to OBR/
STAT3 association, but no activation of STAT3. Leptin on
its turn, phosphorylates and activates JAK2, which leads to
OBR tyrosine phosphorylation and STAT3 recruitment ac-
companied by its activation. Co-stimulation with insulin and
leptin provides an additive signal which leads to enhanced
STAT3 association and nuclear activation.
Integrated responses to insulin and leptin in the hypothal-
amus participate in the physiological control of food ingestion
and body weight. The clinical outcomes observed in some
animal models and in humans may re£ect a disruption of
the normal events in either of these signaling pathways. Obe-
sity occurs in mice lacking the IR in the central nervous sys-
tem (NIRKO) [19], despite elevated circulating leptin concen-
trations. This suggests that organ-speci¢c insulin resistance in
the central nervous system leads to central leptin resistance.
On the other hand, the lack of leptin in ob/ob mice leads to
obesity accompanied by hyperinsulinemia, which by itself is
not su⁄cient to reverse the obese phenotype. Finally, in hu-
mans with type 1 diabetes, a hypoinsulinemic and a hypolep-
tinemic status may contribute to the ensuing hyperphagia.
Thus insulin resistance, as well as a complete absence of in-
sulin, may impair some of the leptin responses. Our results
indicate a mechanism for modulation of the leptin/STAT3
signal transduction pathway by insulin. Insulin rapidly in-
creased the phosphorylation of OBR, and improved the stim-
ulation of leptin-mediated STAT3 phosphorylation, with a
consequent gain in STAT3 signaling to the nucleus. This
Fig. 6. Model for insulin/leptin cross-talk in rat hypothalamus. A: Insulin infusion. The phosphorylated IR binds and phosphorylates JAK2,
which phosphorylates the leptin receptor. The leptin receptor binds STAT3, but there is no nuclear activation. B: Leptin infusion. The leptin
receptor binds and activates JAK2, which phosphorylates the leptin receptor. The leptin receptor then binds and activates STAT3. C: Insulin+-
leptin infusion. The simultaneous stimulation with insulin and leptin delivers an addictive signal, which leads to enhanced STAT3 association
and nuclear activation.
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mechanism may normally function to potentiate the activity
of both of these pathways, and to increase stimulation in
physiological processes such as the regulation of body weight
and food intake, that are under the combined control of in-
sulin and leptin. The potential for this interaction as a site for
new therapeutic approaches in treating leptin resistance, and
for increasing our understanding of leptin signaling and tyro-
sine kinase-mediated pathways, deserves further exploration.
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